Sodium oxybate therapy for the treatment of alcohol withdrawal syndrome and the maintenance of alcohol abstinence

Mannucci, C.; Pichini, S.; Spagnolo, E.; Calapai, F.; Gangemi, S.; Navarra, M.; Calapai, G.

Risultato della ricerca: Article

Abstract

Gamma-hydroxybutyrate (GHB or sodium oxybate) is both an exogenous and endogenous molecule with neuromodulator properties. In the United States, GHB is an approved drug for the treatment of narcolepsy and narcolepsy with cataplexy in adults. In some European Union countries, sodium oxybate is applied for the treatment of opioid and alcohol withdrawal.
Lingua originaleEnglish
pagine (da-a)-
Numero di pagine9
RivistaCurrent Drug Metabolism
Volume19
Stato di pubblicazionePublished - 2017

Fingerprint

Alcohol Abstinence
Sodium Oxybate
Narcolepsy
Maintenance
Alcohols
Cataplexy
European Union
Opioid Analgesics
Neurotransmitter Agents
Therapeutics
Molecules
Pharmaceutical Preparations

Cita questo

Mannucci, C.; Pichini, S.; Spagnolo, E.; Calapai, F.; Gangemi, S.; Navarra, M.; Calapai, G. (2017). Sodium oxybate therapy for the treatment of alcohol withdrawal syndrome and the maintenance of alcohol abstinence. Current Drug Metabolism, 19, -.

Sodium oxybate therapy for the treatment of alcohol withdrawal syndrome and the maintenance of alcohol abstinence. / Mannucci, C.; Pichini, S.; Spagnolo, E.; Calapai, F.; Gangemi, S.; Navarra, M.; Calapai, G.

In: Current Drug Metabolism, Vol. 19, 2017, pag. -.

Risultato della ricerca: Article

Mannucci, C.; Pichini, S.; Spagnolo, E.; Calapai, F.; Gangemi, S.; Navarra, M.; Calapai, G. 2017, 'Sodium oxybate therapy for the treatment of alcohol withdrawal syndrome and the maintenance of alcohol abstinence', Current Drug Metabolism, vol. 19, pagg. -.
Mannucci, C.; Pichini, S.; Spagnolo, E.; Calapai, F.; Gangemi, S.; Navarra, M.; Calapai, G. Sodium oxybate therapy for the treatment of alcohol withdrawal syndrome and the maintenance of alcohol abstinence. Current Drug Metabolism. 2017;19:-.
Mannucci, C.; Pichini, S.; Spagnolo, E.; Calapai, F.; Gangemi, S.; Navarra, M.; Calapai, G. / Sodium oxybate therapy for the treatment of alcohol withdrawal syndrome and the maintenance of alcohol abstinence. In: Current Drug Metabolism. 2017 ; Vol. 19. pagg. -.
@article{5bac3ea01e964a00add61b40cf7bb7cb,
title = "Sodium oxybate therapy for the treatment of alcohol withdrawal syndrome and the maintenance of alcohol abstinence",
abstract = "Gamma-hydroxybutyrate (GHB or sodium oxybate) is both an exogenous and endogenous molecule with neuromodulator properties. In the United States, GHB is an approved drug for the treatment of narcolepsy and narcolepsy with cataplexy in adults. In some European Union countries, sodium oxybate is applied for the treatment of opioid and alcohol withdrawal.",
author = "{Mannucci, C.; Pichini, S.; Spagnolo, E.; Calapai, F.; Gangemi, S.; Navarra, M.; Calapai, G.} and {Ventura Spagnolo}, Elvira",
year = "2017",
language = "English",
volume = "19",
pages = "--",
journal = "Current Drug Metabolism",
issn = "1389-2002",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Sodium oxybate therapy for the treatment of alcohol withdrawal syndrome and the maintenance of alcohol abstinence

AU - Mannucci, C.; Pichini, S.; Spagnolo, E.; Calapai, F.; Gangemi, S.; Navarra, M.; Calapai, G.

AU - Ventura Spagnolo, Elvira

PY - 2017

Y1 - 2017

N2 - Gamma-hydroxybutyrate (GHB or sodium oxybate) is both an exogenous and endogenous molecule with neuromodulator properties. In the United States, GHB is an approved drug for the treatment of narcolepsy and narcolepsy with cataplexy in adults. In some European Union countries, sodium oxybate is applied for the treatment of opioid and alcohol withdrawal.

AB - Gamma-hydroxybutyrate (GHB or sodium oxybate) is both an exogenous and endogenous molecule with neuromodulator properties. In the United States, GHB is an approved drug for the treatment of narcolepsy and narcolepsy with cataplexy in adults. In some European Union countries, sodium oxybate is applied for the treatment of opioid and alcohol withdrawal.

UR - http://hdl.handle.net/10447/281941

M3 - Article

VL - 19

SP - -

JO - Current Drug Metabolism

JF - Current Drug Metabolism

SN - 1389-2002

ER -